Pharmacokinetic strategies in deciphering atypical drug absorption profiles

Journal of Clinical Pharmacology

Volumn 43, Issue 3, 2003, Pages 211-227

  Zhou, Honghui ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSPORT; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; MAXIMUM ALLOWABLE CONCENTRATION;

ADMINISTRATION, ORAL; AGE FACTORS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SEX FACTORS; TIME FACTORS;

EID: 0037370813     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002250613     Document Type: Article

References (107)

1. Teorell T: Kinetics of distribution of substances administered to the body. Arch Intern Pharmocodyn 1937;57:205-240.
2. Thummel KE, Kunze KL, Shen DD: Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Del Rev 1997;27:99-127.
3. Doherty M, Charman W: The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Phormacokinet 2002;41(4):235-253.
4. Olson JA, Moon RC, Anders MW, Fenselau C, Shane B: Enhancement of biological activity by conjugation reactions. J Nutr 1992; 122(Suppl.):615-624.
5. Sonne J: Factors and conditions affecting the glucuronidation of oxazepam. Pharmacol Toxicol 1993;73(Suppl. 1):1-23.
6. Ilett KF, Dollery CT, Davies DS: Isoprenaline conjugation: a "true first-pass effect" in the dog intestine. J Pharm Pharmocol 1980; 32(5):362.
7. Geroge CF: Drug metabolism by the gastrointestine mucosa. Clin Pharmacokinet 1981;6(4):259-274.
8. Ayrton A, Morgan P: Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001;31:469-497.
9. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Rockmoller J, Johne A, et al: Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Nat Acad Sci USA 2000;97:3473-3478.
10. Sharom FJ: The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997;160:161-175.
11. Martinez M, Amidon G: A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002;42:620-643.
12. Zhang Y, Gan X, Lin ET, Benet LZ: Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos 1998;26(4):360-366.
13. Benet LZ, Wu C-Y, Hebert MF, et al: Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Control Rel 1996;39:139-143.
14. Gan LS, Mosely MA, Khosla B, et al: CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cylosporin A in caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 1996;24:344-349.
15. Watkins PB: The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Del Rev 1997;27:161-170.
16. Benet LZ, Cummins CL: The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Del Rev 2001;50:S3-S11.
17. Hebert MF: Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Del Rev 1997;27:201-214.
18. Borst P, Evers R, Lool M, et al: The multidrug resistance protein family. Biochim Biophys Acta 1999;1461:347-357.
19. Taylor EM: The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002; 41(2):81-92.
20. Halestrap AP, Price NT: The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999;343:281-299.
21. Wagner JG: Appraisal of digoxin bioavailability and pharmacokinetics in relation to cardiac therapy. Am Heart J 1974;88:133-138.
22. Iialo E: Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 1977;2:1-6.
23. Dunne A, Corrigan OI, Bottini PB, Geoghegan EJ: Proc. 2nd European Congress of Biopharmaceutics and Pharmacokinetics, vol. 1, Salamanca, Spain, 1984.
24. Menton A, Ritschel WA, Sakr A: Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci 1994; 83:239-245.
25. Smal J, Marvola M, Lijequist C, Happonen I: Prolonged-release hydroxypropyl methylcellulose matrix tablets of furosemide for administration to dogs. J Vet Pharmacol Ther 1996;19:482-487.
26. Akiyama Y, Nagahara N, Nara E, Kitano M, Iwasa S, Yamamoto I, et al: Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites. J Pharm Pharmacol 1998;50:159-166.
27. Terao T, Matsuda K, Shouji H: Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55. J Pharm Pharmacol 2001;53:433-440.
28. Sawamoto T, Haruta S, Kurosaki Y, Higaki K, Kimura T: Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability. J Pharm Pharmacol 1997;49(4):450-457.
29. Haruta S, Iwasaki N, Ogawara KI, Higaki K, Kimura T: Absorption behavior of orally administered drugs in rats treated with propantheline. J Pharm Sci 1998;87(9):1081-1085.
30. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Philadelphia: Lippincott/Williams & Wilkins, 1995.
31. Klotz U: Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Ther 1998;36(11):581-585.
32. Kearns GL, Reed MD: Clinical pharmacokinetics in infants and children: a reappraisal. Clin Pharmacokinet 1989;17(Suppl. 1):29-67.
33. Stewart C, Hampton EM: Effect of maturation on drug disposition in pediatric patients. Clin Pharm 1987;6:548-564.
34. Capparelli EV: Pharmacokinetic considerations in the adolescent: non-cytochrome P450 metabolic pathways. J Adolescent Health 1994;15:641-647.
35. van den Anker JN: Pharmacokinetics and renal function in preterm infants. Acta Pediatr 1996;85:1393-1399.
36. Fletcher CV, Acosta EP, Strykowski JM: Gender differences in human pharmacokinetics and pharmacodynamics. J Adolescent Health 1994;15:619-629.
37. Woodhead JC, Drulis JM, Nelson SE, Janghorbani M, Fomon SJ: Gender-related differences in iron absorption by preadolescent children. Pediatr Res 1991;29:435-439.
38. Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS: High blood alcohol levels in women, the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990;322:95-99.
39. Parker WA: Effects of pregnancy on pharmacokinetics, in: Benet LZ, Massoud N, Gmabertoglio JG (eds.), Pharmacokinetic Basis for Drug Treatment. New York: Raven, 1984.
40. Johnson JA: Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 2000; 38(2):53-60.
41. Amidon GL, Lennernas H, Shah VP, Crison JR: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12(3):413-420.
42. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Rockville, MD: Food and Drug Administration, 2000.
43. Young DB, Devane JG, Butler J: In Vitro-In Vivo Correlation. New York: Plenum, 1997.
44. Scheen AJ: Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30(5):359-371.
45. Balan G, Timmins P, Greene DS, Marathe PH: In vitro-in vivo correlation (IVIVC) models for metformin after administration of modifiedrelease (MR) oral dosage forms to healthy human volunteers. J Pharm Sci 2001;90(8):1176-1185.
46. Gerardin A, Wantiez D, Jaouen A: An incremental method for the study of the absorption of drugs whose kinetics are described by a two-compartment model: estimation of the microscopic rate constants. J Pharmacokinet Biopharm 1983;11(4):401-425.
47. Ronfeld R, Benet LZ: Interpretation of plasma concentration-time curves after oral dosing. J Pharm Sci 1977;66(2):178-180.
48. Chan KKH, Gibaldi M: Assessment of drug absorption after oral administration. J Pharm Sci 1985;74(4):388-393.
49. Purves RD: Anomalous parameter estimates in the onecompartment model with first-order absorption. J Pharm Pharmacol 1993;45:934-936.
50. Chan KKH, Gibaldi M: Evaluation drug absorption after oral administration: some problems and some solutions. Eur J Clin Pharmacol 1984;26:255-259.
51. Grevel J, Nüesch E, Abisch E, Kutz K: Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol 1986;31:211-216.
52. Cooke AR: The simultaneous emptying and absorption of ethanol from the human stomach. Am J Dig Dis 1970;15:449-454.
53. Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M: Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular and oral administration to man. J Pharm Sci 1972;61:773-778.
54. Bates TR, Carrigan PJ: Apparent absorption kinetics of micronized griseofulvin after its oral administration on single- and multiple-dose regimens to rats as a corn oil-in-water emulsion and aqueous suspension. J Pharm Sci 1975;64(9):1475-1481.
55. Colburn WA, Di Santo AR, Gibaldi M: Pharmacokinetics of erythromycin on repetitive dosing. J Clin Pharmacol 1977;17(10, Pt. 1):592-600.
56. McNamara PJ, Colburn WA, Gibaldi M: Absorption kinetics of hydroflumethiazide. J Clin Pharmacol 1978;18(4):191-193.
57. Cheng H, Jusko WJ: The area function method for assessing the drug absorption rate in linear systems with zero-order input. Pharm Res 1989;6(2):133-139.
58. Cheng H, Jusko WJ: Effects of variation in drug elimination on five methods for assessing zero-order drug absorption rates. Pharm Res 1990;7(1):76-79.
59. Riegelman S, Collier P: The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8(5):509-534.
60. Liu X, Brouwer KLR, Pollack GM: A modified residual method to estimate the zero-order absorption rate constant in a one-compartment model. Biopharm Drug Dispos 1997;18(2):93-101.
61. Troconiz IF, Armenteros S, Planelles MV, Benitez J, Calvo R, Dominguez R: Pharmacokinetic-pharmacodynamic modelling of the antipyretic effect of two oral formulations of ibuprofen. Clin Pharmacokinet 2000;38(6):505-518.
62. Burm AG, Vermeulen NP, van Kleef JW, de Boer AG, Spierdijk J, Breimer DD: Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration: simultaneous investigation of absorption and disposition kinetics using stable isotopes. Clin Pharmacokinet 1987;13(3):191-203.
63. Ogiso T, Ito Y, Iwaki M, Atago H, Yamamoto Y: A pharmacokinetic model for percutaenous absorption of valproic acid and prediction of drug disposition. J Pharmacobiodyn 1988;11(6):444-452.
64. Zhou H, Chen TL, Marino M, Lau H, Miller T, Kalafsky G, et al: Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. Br J Clin Pharmacol 2000; 50(6):543-552.
65. Gabrielsson J, Weiner D: Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications. 3rd ed. Stockholm: Swedish Pharmaceutical Press, 2000.
66. Murata K, Yamahara H, Kobayashi M, Noda K, Samejima M: Pharmacokinetics of an oral sustained-release diltiazem preparation. J Pharm Sci 1989;78(11):960-963.
67. Murata K, Noda K, Kohno K, Samejima M: Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models. J Pharm Sci 1987;76(2): 109-113.
68. Mahmood I: Pharmacokinetic analysis of the absorption characteristics of diclofenac sodium in man by use of a multi-segment absorption model. J Pharm Pharmacol 1996;48:1260-1263.
69. Veng-Pedersen P: Pharmacokinetics and bioavailability of cimetidine in human. J Pharm Sci 1980;75:394-398.
70. Aldous S, Thomas R: Absorption and metabolism of lanatoside C: II. Fate after oral administration. Clin Pharmacol Ther 1977; 21(6):647-658.
71. Bergstrom RF, Kay D, Harkcom TM, Wagner JG: Penicillamine kinetics in normal subjects. Clin Pharmacol Ther 1981;30(3):404-413.
72. Veng Pedersen P: Pharmacokinetic analysis by linear system approach: I. Cimetidine bioavailability and second peak phenomenon. J Pharm Sci 1981;70:32-38.
73. Beerman B: Value of plasma digoxin estimation. Lancet 1973;1:375.
74. Parquet M, Metman EH, Raizman A, Rambaud JC, Berthaux N, Infante R: Bioavailability, gastrointestinal transit, solubilization and faecal excretion of urosodeoxycholic acid in man. Eur J Clin Invest 1985;15:171-178.
75. Plusquellec Y, Campistron G, Staveris S, Barre J, Jung L, Tillement JP, Houin G: A double-peak phenomena in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 1987;15:225-239.
76. Holgate AM, Read NW: Effect of ileal infusions on intralipid on gastrointestinal transit, ileal flow rate, and carbohydrate absorption in humans after ingestion of a liquid meal. Gastronenterology 1985; 88:1005-1011.
77. Oberle RL, Amidon GL: The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine: an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 1987;15(5):529-544.
78. Lipka E, Lee I-D, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL: Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 1995;23(3):267-287.
79. Wang Y, Roy A, Sun L, Lau CE; A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 1999;27(8):855-859.
80. Marathe PH, Sandefer EP, Kollia GE, Greene DS, Barbhaiya RH, Lipper RA, et al: In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy. J Pharmacokinet Biopharm 1998;26(1):1-9.
81. Charman WN, Rogge M, Boddy AW, Barr WH, Berger BM: Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles. J Clin Pharmucol 1993;33:1207-1213.
82. Holford NH, Ambros RJ, Stoeckel K: Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm 1992;20(5);421-442.
83. Garrigues TM, Martin U, Peris-Ribera JE, Prescott LF: Dose-dependent absorption and elimination of cefadroxil in man. Eur J Clin Pharmacol 1991;41(2):179-183.
84. Cosson VF, Fuseau E: Mixed effect modeling of sumatriptan pharmacokinetics during development: II. From healthy subjects to phase 2 dose ranging in patients. J Pharmacokinet Biopharm 1999; 27(2):149-171.
85. Bouzom F, Laveille C, Merdjan H, Jochemsen R: Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat. J Pharm Sci 2000;89(5):603-613.
86. Rietbrock S, Merz PG, Fuhr U, Harder S, Marschner JP, Loew D, et al: Absorption behavior of sulpiride described using Weibull functions. Int J Clin Pharmacol Ther 1995;33(5):299-303.
87. Christensen FN, Hansen FG, Bechgaard H: Physical interpretation of parameters in the Rosin-Rammler-Sperling-Weibull distribution for drug release from controlled-release dosage forms. J Pharm Pharmacol 1980;32:580-582.
88. Piotrovskii VK: The use of Weibull distribution to describe the in vivo absorption kinetics. J Pharmacokinet Biopharm 1987;15(6): 681-686.
89. Smith D, Enever R, Dey M, Latta D, Weierstall R: Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. Biopharm Drug Dispos 1993;14:341-355.
90. Padoin C, Tod M, Brion N, Louchahi K, Le Gros V, Petitjean O: Pharmacokinetics of amoxicillin coadministered with a salinepolyethylene glycol solution in healthy volunteers. Biopharm Drug Dispos 1995;16:169-176.
91. Bressolle F, Gomeni R, Alric R, Royer-Morrot MJ, Necciari J: A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. J Pharm Sci 1994;83(10): 1461-1464.
92. Zhou H, Khalilieh S, Lau H, Guerret M, Osborne S, Laurent A, McLeod J: Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF919). J Clin Pharmacol 1999;39(9):911-920.
93. Hartmann D, Gysel D, Dubach UC, Forgo I: Pharmacokinetic modelling of the plasma concentration-time profile of the vitamin retinyl palmitate following intramuscular administration. Biopharm Drug Disp 1990;11:689-700.
94. Couet WR, Reginer BG, Guedes JP, Tozer YN. Theoretical model for both saturable rate and extent of absorption: simulations of cefatrizine data. J Pharmacokinet Biopharm 1991;19:271-285.
95. Levy G, Jusko WJ: Factors affecting the absorption of riboflavin in man. J Pharm Sci 1966;55:285-289.
96. Gladtke E, von Hattingberg H-M: Pharmacokinetics. Berlin: Springer, 1979.
97. Wood JH, Thakker KM: Michaelis-Menten absorption kinetics in drugs: examples and implications. Eur J Clin Pharmacol 1982; 23:183-188.
98. Liu XD, Xie L, Gao JP, Lai LS, Liu GD: Cefixime absorption kinetics after oral administration to humans. Eur J Drug Metab Phormacokinet 1997;22(2):185-188.
99. Cox SR, Harrington EL, Capponi VJ: Bioavailability studies with ciglitazone in beagles: II. Effect of propantheline bromide and metoclopramide HCL on bioavailability of a tablet. Biopharmaceutics & Drug Disposition 1985;6:81-90.
100. Higaki K, Yamashita S, Amidon GL: Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn 2001;28(2):109-128.
101. Weiss M: A novel extravascular input function for the assessment of drug absorption in bioavailability studies. Pharm Res 1996;13(10):1547-1553.
102. Weiss M, Hubner GH, Hubner IG, Teichmann W: Effects of cardiac output on disposition kinetics of sorbitol: recirculatory modelling. Br J Clin Pharmacol 1996;41(4):261-268.
103. Weiss M, Stedtler C, Roberts MS: On the validity of the dispersion model of hepatic drug elimination when intravascular transit time densities are long-tailed. Bull Math Biol 1997;59(5):911-929.
104. Roberts MS, Anissimov YG, Weiss M: Commentary: using the convection-dispersion model and transit time density functions in the analysis of organ distribution kinetics. J Pharm Sci 2000; 89(12):1579-1586.
105. Zhang X, Nieforth K, Lang J-M, Rouzier-Panis R, Reynes J, Dorr A, et al: Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002;72:10-19.
106. Rietbrock S, Keller-Stanislawski, Thurmann P, Brockmeier D: Pharmacokinetic profile of a novel slow release preparation of molsidomine. Eur J Clin Pharmacol 1992;43(3):273-276.
107. Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM: Oral absorpqtion characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol 1996; 36(10):874-883.